Gregory Von Mering is a notable inventor based in Gainesville, FL (US). He has made significant contributions to the field of thrombolytic therapy, holding a total of 3 patents. His work focuses on innovative methods and compositions that enhance medical treatments.

Latest Patents

One of Gregory's latest patents involves bacterial plasmin receptors as fibrinolytic agents. This invention concerns novel methods and compositions for thrombolytic therapy. Specifically, a receptor with high affinity for plasmin has been characterized, purified, cloned, and expressed. This receptor can be utilized in combination therapies, administered prior to, concurrently with, or after a plasminogen activator. Additionally, the receptor can be bound to plasmin and administered to humans or animals in need of fibrinolytic activity. The invention also pertains to a novel immobilized form of plasmin, which advantageously accumulates at the point where antifibrinolytic activity is needed.

Career Highlights

Gregory Von Mering is affiliated with the University of Florida Research Foundation, Incorporated. His work has been instrumental in advancing therapeutic options for patients requiring fibrinolytic treatments. His innovative approaches have the potential to significantly improve patient outcomes in thrombolytic therapy.

Collaborations

Gregory has collaborated with notable colleagues, including Michael D Boyle and Richard Lottenberg. These partnerships have fostered a collaborative environment that enhances research and development in the field.

Conclusion

Gregory Von Mering's contributions to thrombolytic therapy through his innovative patents and collaborations highlight his role as a leading inventor in the medical field. His work continues to pave the way for advancements in treatment methodologies.